Evidence map›Paper›PMID 35884904›Full record

ReviewBiomedicines2022

Molecular Mechanisms of Autophagy in Cancer Development, Progression, and Therapy.

Veronica Angela Maria Vitto, Silvia Bianchin, Alicia Ann Zolondick, Giulia Pellielo, Alessandro Rimessi, Diego Chianese, Haining Yang, Michele Carbone, Paolo Pinton, Carlotta Giorgi and 1 more

Abstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Veronica Angela Maria VittoLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-7189-350X
Silvia BianchinLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.
Alicia Ann ZolondickThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816, USA.
Giulia PellieloLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-4347-935X
Alessandro RimessiLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-7091-5765
Diego ChianeseLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.
Haining YangThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816, USA.
Michele CarboneThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816, USA.
Paolo PintonLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-7108-6508
Carlotta GiorgiLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-2494-7405
Simone PatergnaniLaboratory for Technologies of Advanced Therapies (LTTA), Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-7951-9267

Funding

Mechanisms of BAP1 activity in human cancer developmentR01CA237235 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, YANG, HAINING · 2020 to 2024
$2.1M
Influence of germline mutations on susceptibility to environmental carcinogensR01ES030948 · NIEHS · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, GRZYMSKI, JOSEPH J · 2019 to 2021
$1.9M
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7M
Associazione Ricerca Oncologica Sperimentale EstenseEuropean Council InflaPML 853057Italian Association for Cancer Research IG-19803Italian Association for Cancer Research IG-23670Ministero della Salute GR-2013-02356747NCI NIH HHS 1R01CA198138NCI NIH HHS 1R01CA237235-01A1NCI NIH HHS R01 CA198138NCI NIH HHS R01 CA237235NIEHS NIH HHS R01 ES030948United States Department of Defense W81XWH-16-1-0440
6 · The paper itself

Abstract

Autophagy is an evolutionarily conserved and tightly regulated process that plays an important role in maintaining cellular homeostasis. It involves regulation of various genes that function to degrade unnecessary or dysfunctional cellular components, and to recycle metabolic substrates. Autophagy is modulated by many factors, such as nutritional status, energy level, hypoxic conditions, endoplasmic reticulum stress, hormonal stimulation and drugs, and these factors can regulate autophagy both upstream and downstream of the pathway. In cancer, autophagy acts as a double-edged sword depending on the tissue type and stage of tumorigenesis. On the one hand, autophagy promotes tumor progression in advanced stages by stimulating tumor growth. On the other hand, autophagy inhibits tumor development in the early stages by enhancing its tumor suppressor activity. Moreover, autophagy drives resistance to anticancer therapy, even though in some tumor types, its activation induces lethal effects on cancer cells. In this review, we summarize the biological mechanisms of autophagy and its dual role in cancer. In addition, we report the current understanding of autophagy in some cancer types with markedly high incidence and/or lethality, and the existing therapeutic strategies targeting autophagy for the treatment of cancer.

Indexed as

anoikisautophagycancertherapytumor promotiontumor suppression

Identifiers

PMID35884904
PMCPMC9313210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.